TSE:PLI - ProMetic Life Sciences Stock Price, News & Analysis

C$12.67
+0.36 (+2.92 %)
(As of 08/19/2019 02:09 PM ET)
Today's Range
C$12.55
Now: C$12.67
C$13.50
50-Day Range
C$0.02
MA: C$13.86
C$20.25
52-Week Range
C$7.13
Now: C$12.67
C$720.00
Volume31,360 shs
Average Volume7,943 shs
Market CapitalizationC$295.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-450-7810115

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$51.32 million
Cash FlowC$0.45 per share
Book ValueC($104.07) per share

Profitability

Miscellaneous

Employees487
Market CapC$295.38 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive PLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter.


ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."

When is ProMetic Life Sciences' next earnings date?

ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for ProMetic Life Sciences.

What price target have analysts set for PLI?

4 brokers have issued 12-month price objectives for ProMetic Life Sciences' stock. Their forecasts range from C$0.30 to C$0.70. On average, they expect ProMetic Life Sciences' stock price to reach C$0.43 in the next twelve months. This suggests that the stock has a possible downside of 96.6%. View Analyst Price Targets for ProMetic Life Sciences.

What is the consensus analysts' recommendation for ProMetic Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ProMetic Life Sciences.

Has ProMetic Life Sciences been receiving favorable news coverage?

Media headlines about PLI stock have been trending negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ProMetic Life Sciences earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for ProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

What other stocks do shareholders of ProMetic Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProMetic Life Sciences investors own include Nemaska Lithium (NMX), ProMetic Life Sciences (PFSCF), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG), Sierra Wireless (SWIR), Baytex Energy (BTE), Aurora Cannabis (ACB), Dollarama (DOL), Parkland Fuel (PKI) and Resverlogix (RVX).

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:
  • Mr. Kenneth H. Galbraith, CEO & Director (Age 56)
  • Mr. Bruce Pritchard, International COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
  • Dr. John Moran, Chief Medical Officer (Age 73)

How do I buy shares of ProMetic Life Sciences?

Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of PLI stock can currently be purchased for approximately C$12.67.

How big of a company is ProMetic Life Sciences?

ProMetic Life Sciences has a market capitalization of C$295.38 million and generates C$51.32 million in revenue each year. ProMetic Life Sciences employs 487 workers across the globe.View Additional Information About ProMetic Life Sciences.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is http://prometic.com/.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.


MarketBeat Community Rating for ProMetic Life Sciences (TSE PLI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  401 (Vote Outperform)
Underperform Votes:  302 (Vote Underperform)
Total Votes:  703
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel